📍 WASHINGTON D.C., USA
31.10.2026
FDA Faces Complex Regulatory Battle Over Proposed Revocation of Kidney Drug Tavneos
The United States Food and Drug Administration has initiated procedural efforts to withdraw its commercial approval for Tavneos, a specialized medication prescribed for rare autoimmune kidney disorders, citing fundamenta...